'Now you are going overboard': After Bombay high court rap, FDA withdraws order cancelling licence of Cipla Pharma
The FDA said it would withdraw the licence cancellation order forthwith and issue a fresh show cause notice to Cipla Pharma.
The Bombay High Court has ordered the Maharashtra Food and Drug Administration (FDA) to withdraw its decision to cancel Cipla Pharma & Life Sciences Limited's drug sale licence at their Pune unit. The FDA had previously cancelled the licences due to serious irregularities related to the packaging, storage, and recall of Reactin Plus Tablets.
Acting Chief Justice Ravindra Ghuge and Justice Gautam Ankhad criticized the FDA for violating principles of natural justice, behaving in a high-handed manner and following a flawed procedure. The FDA had sent an email instructing the company to appear for a hearing on a public holiday, but the company could not provide a representative.
The court questioned the fairness and transparency of the FDA's actions, emphasizing the need for a reasoned order.
Written by urgent.news from Hindustan Times's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- FDA Withdraws Cipla Pune Licence Cancellation After Bombay HC Rebuke freepressjournal.in
